Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Pascual Sánchez-Juan, Elizabeth Valeriano-Lorenzo, Alicia Ruiz-González, Ana Belén Pastor, Hector Rodrigo Lara, Francisco López-González, María Ascensión Zea-Sevilla, Meritxell Valentí, Belen Frades, Paloma Ruiz, Laura Saiz, Iván Burgueño-García, Miguel Calero, Teodoro Del Ser, Alberto Rábano
Glial fibrillary acidic protein (GFAP), a proxy of astrocyte reactivity, has been proposed as biomarker of Alzheimer's disease. However, there is limited information about the correlation between blood biomarkers and post-mortem neuropathology. In a single-centre prospective clinicopathological cohort of 139 dementia patients, for which the time-frame between GFAP level determination and neuropathological assessment was exceptionally short (on average 139 days), we analysed this biomarker, measured at three time points, in relation to proxies of disease progression such as cognitive decline and brain weight...
April 18, 2024: Brain
#2
JOURNAL ARTICLE
Michael Gilligan, Connie E Lesnick, Yong Guo, Michael J Bradshaw, Shafeeq S Ladha, Mihaela Nowak, Maulik P Shah, John R Wittenborn, Eati Basal, Shannon Hinson, Binxia Yang, Divyanshu Dubey, John R Mills, Sean J Pittock, Anastasia Zekeridou, Andrew McKeon
OBJECTIVES: To report an autoimmune paraneoplastic encephalitis characterized by immunoglobulin G (IgG) antibody targeting synaptic protein calmodulin kinase-like vesicle-associated (CAMKV). METHODS: Serum and cerebrospinal fluid (CSF) samples harboring unclassified antibodies on murine brain-based indirect immunofluorescence assay (IFA) were screened by human protein microarray. In 5 patients with identical cerebral IFA staining, CAMKV was identified as top-ranking candidate antigen...
April 18, 2024: Annals of Neurology
#3
REVIEW
Irene Cortese, Gina Norato, Patrick R Harrington, Therri Usher, Ilaria Mainardi, Guillaume Martin-Blondel, Paola Cinque, Eugene O Major, Virginia Sheikh
Progressive multifocal leukoencephalopathy is a rare but devastating demyelinating disease caused by the JC virus (JCV), for which no therapeutics are approved. To make progress towards addressing this unmet medical need, innovations in clinical trial design are needed. Quantitative JCV DNA in CSF has the potential to serve as a valuable biomarker of progressive multifocal leukoencephalopathy disease and treatment response in clinical trials to expedite therapeutic development, as do neuroimaging and other fluid biomarkers such as neurofilament light chain...
May 2024: Lancet Neurology
#4
JOURNAL ARTICLE
Julie K Wisch, Nicole S McKay, Anna H Boerwinkle, James Kennedy, Shaney Flores, Benjamin L Handen, Bradley T Christian, Elizabeth Head, Mark Mapstone, Michael S Rafii, Sid E O'Bryant, Julie C Price, Charles M Laymon, Sharon J Krinsky-McHale, Florence Lai, H Diana Rosas, Sigan L Hartley, Shahid Zaman, Ira T Lott, Dana Tudorascu, Matthew Zammit, Adam M Brickman, Joseph H Lee, Thomas D Bird, Annie Cohen, Patricio Chrem, Alisha Daniels, Jasmeer P Chhatwal, Carlos Cruchaga, Laura Ibanez, Mathias Jucker, Celeste M Karch, Gregory S Day, Jae-Hong Lee, Johannes Levin, Jorge Llibre-Guerra, Yan Li, Francisco Lopera, Jee Hoon Roh, John M Ringman, Charlene Supnet-Bell, Christopher H van Dyck, Chengjie Xiong, Guoqiao Wang, John C Morris, Eric McDade, Randall J Bateman, Tammie L S Benzinger, Brian A Gordon, Beau M Ances
BACKGROUND: In people with genetic forms of Alzheimer's disease, such as in Down syndrome and autosomal-dominant Alzheimer's disease, pathological changes specific to Alzheimer's disease (ie, accumulation of amyloid and tau) occur in the brain at a young age, when comorbidities related to ageing are not present. Studies including these cohorts could, therefore, improve our understanding of the early pathogenesis of Alzheimer's disease and be useful when designing preventive interventions targeted at disease pathology or when planning clinical trials...
May 2024: Lancet Neurology
#5
JOURNAL ARTICLE
Timoleon Siempis, Spyridon Voulgaris, George A Alexiou
No abstract text is available yet for this article.
April 6, 2024: Clinical Neurology and Neurosurgery
#6
REVIEW
Lin Wang, Yubing Hu, Nan Jiang, Ali K Yetisen
Psychiatric disorders are associated with serve disturbances in cognition, emotional control, and/or behavior regulation, yet few routine clinical tools are available for the real-time evaluation and early-stage diagnosis of mental health. Abnormal levels of relevant biomarkers may imply biological, neurological, and developmental dysfunctions of psychiatric patients. Exploring biosensors that can provide rapid, in-situ, and real-time monitoring of psychiatric biomarkers is therefore vital for prevention, diagnosis, treatment, and prognosis of mental disorders...
March 29, 2024: Biosensors & Bioelectronics
#7
JOURNAL ARTICLE
Michael Zhong, Sabrina Salberg, Sandeep Sampangi, Anneke van der Walt, Helmut Butzkueven, Richelle Mychasiuk, Vilija Jokubaitis
BACKGROUND: Aging-related processes contribute to neurodegeneration and disability in multiple sclerosis (MS). Biomarkers of biological aging such as leukocyte telomere length (LTL) could help personalise prognosis. Pregnancy has been shown to be protective against disability accumulation in women with MS, though it is unclear if this effect relates to aging mechanisms or LTL. OBJECTIVES: This study aimed to cross-sectionally characterise LTL in a cohort of individuals with MS, and to correlate LTL with disability severity and pregnancy history...
April 10, 2024: Multiple Sclerosis and related Disorders
#8
JOURNAL ARTICLE
Etienne Fortanier, Marc Adrien Hostin, Constance Michel, Emilien Delmont, Marc-Emmanuel Bellemare, Maxime Guye, David Bendahan, Shahram Attarian
BACKGROUND AND OBJECTIVES: Intramuscular fat fraction (FF) assessed using quantitative MRI (qMRI) has emerged as one of the few responsive outcome measures in CMT1A suitable for future clinical trials. This study aimed to identify the relevance of multiple qMRI biomarkers for tracking longitudinal changes in CMT1A and to assess correlations between MRI metrics and clinical parameters. METHODS: qMRI was performed in CMT1A patients at 2 time points, a year apart, and various metrics were extracted from 3-dimensional volumes of interest at thigh and leg levels...
May 14, 2024: Neurology
#9
JOURNAL ARTICLE
Bhavna Gupta, Akash Saxena, Mason L Perillo, Lauren C Wade-Kleyn, Cort H Thompson, Erin K Purcell
ConspectusImplantable neurotechnology enables monitoring and stimulating of the brain signals responsible for performing cognitive, motor, and sensory tasks. Electrode arrays implanted in the brain are increasingly used in the clinic to treat a variety of sources of neurological diseases and injuries. However, the implantation of a foreign body typically initiates a tissue response characterized by physical disruption of vasculature and the neuropil as well as the initiation of inflammation and the induction of reactive glial states...
April 17, 2024: Accounts of Chemical Research
#10
JOURNAL ARTICLE
Homa Seyedmirzaei, Amirhossein Salmannezhad, Hamidreza Ashayeri, Ali Shushtari, Bita Farazinia, Mohammad Mahdi Heidari, Amirali Momayezi, Sara Shaki Baher
Growth-associated protein 43 (GAP-43) is found in the axonal terminal of neurons in the limbic system, which is affected in people with Alzheimer's disease (AD). We assumed GAP-43 may contribute to AD progression and serve as a biomarker. So, in a two-year follow-up study, we assessed GAP-43 changes and whether they are correlated with tensor-based morphometry (TBM) findings in patients with mild cognitive impairment (MCI). We included MCI and cognitively normal (CN) people with available baseline and follow-up cerebrospinal fluid (CSF) GAP-43 and TBM findings from the ADNI database...
April 17, 2024: Neuroinformatics
#11
JOURNAL ARTICLE
Asena Gülçiçek, Elif Şanlı, Gülçin Benbir Şenel, Derya Karadeniz, Özlem Timirci-Kahraman, Cem İsmail Küçükali, Erdem Tüzün
OBJECTIVE: The main pathophysiological mechanisms in restless legs syndrome (RLS) are known as genetic predisposition, brain iron deficiency, and dopaminergic dysfunction. While some genetic variants and polymorphisms were defined, the genetic basis and etiopathogenesis of RLS remain unclear. We aimed to identify new candidate genes and/or potential biomarkers associated with increased RLS risk. METHODS: Twenty-three patients with RLS, 30 patients with Parkinson's disease (PD), and 27 healthy controls were enrolled...
April 17, 2024: Acta Neurologica Belgica
#12
REVIEW
Andreas Wolff, Antonia Franziska Demleitner, Emily Feneberg, Paul Lingor
BACKGROUND: With the increasing development of disease-modifying causative treatment, the importance of early diagnosis and detection of asymptomatic or oligosymptomatic early stages of neurodegenerative diseases is increasing. OBJECTIVE: Presentation of early stages of neurodegenerative diseases, diagnostic procedures for the early detection and possible treatment consequences. MATERIAL AND METHODS: Selective literature search, discussion of basic research and expert recommendations...
April 17, 2024: Der Nervenarzt
#13
REVIEW
Hans-Peter Müller, Jan Kassubek
Neuroimaging biomarkers have shown high potential to map the disease processes in the application to neurodegenerative diseases (NDD), e.g., diffusion tensor imaging (DTI). For DTI, the implementation of a standardized scanning and analysis cascade in clinical trials has potential to be further optimized. Over the last few years, various approaches to improve DTI applications to NDD have been developed. The core issue of this review was to address considerations and limitations of DTI in NDD: we discuss suggestions for improvements of DTI applications to NDD...
2024: Frontiers in Human Neuroscience
#14
JOURNAL ARTICLE
E Mulazzani, L Böhm, T Christmann, M Krumbholz, T Kümpfel, J Havla
BACKGROUND AND PURPOSE: Cryopyrin-associated periodic syndrome is a rare autoinflammatory disease caused by gain-of-function mutations or variants in the NLRP3 gene. Clinically, patients suffer from a broad spectrum of both systemic and neurological symptoms. The aim of this study was to determine whether systemic inflammation demonstrated by serum amyloid A (SAA) elevation is associated with neuroinflammation assessed by optical coherence tomography (OCT). METHODS: Thirty eyes of 15 patients with NLRP3 low penetrance mutations (PwNLRP3) and 20 eyes of 10 age- and sex-matched healthy controls were examined by spectral-domain OCT as part of routine clinical care...
April 16, 2024: European Journal of Neurology
#15
JOURNAL ARTICLE
Jane Alty, Lynette R Goldberg, Eddy Roccati, Katherine Lawler, Quan Bai, Guan Huang, Aidan D Bindoff, Renjie Li, Xinyi Wang, Rebecca J St George, Kaylee Rudd, Larissa Bartlett, Jessica M Collins, Mimieveshiofuo Aiyede, Nadeeshani Fernando, Anju Bhagwat, Julia Giffard, Katharine Salmon, Scott McDonald, Anna E King, James C Vickers
BACKGROUND: Dementia prevalence is predicted to triple to 152 million globally by 2050. Alzheimer's disease (AD) constitutes 70% of cases. There is an urgent need to identify individuals with preclinical AD, a 10-20-year period of progressive brain pathology without noticeable cognitive symptoms, for targeted risk reduction. Current tests of AD pathology are either too invasive, specialised or expensive for population-level assessments. Cognitive tests are normal in preclinical AD...
April 16, 2024: BMC Neurology
#16
JOURNAL ARTICLE
Chaojie Li, Yu Yu, Ningning Li, Ya-Na Yin, Lianjun Zhang, Kehang Xie, Donghui Huang
BACKGROUND: Serum CGRP has been found to increase during migraine attack. However, whether CGRP can identify MA with PFO subtypes in MA remains unknown. This study aimed to investigate the differential expression of calcitonin gene-related peptide (CGRP) between migraine (MA) patients with and without patent foramen ovale (PFO), and to evaluate the predictive value of CGRP for MA with PFO. METHODS: A total of 153 patients with MA, 51 patients with PFO and 102 patients without...
April 16, 2024: BMC Neurology
#17
JOURNAL ARTICLE
Sharifah Azira Taufik, Norlina Ramli, Ai Huey Tan, Shen-Yang Lim, Mohd Taufiq Abdul Ghani, Nortina Shahrizaila
BACKGROUND AND PURPOSE: There is increasing evidence that the anterior visual pathways are involved in neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). This study investigated longitudinal changes in retinal nerve fiber layer (RNFL) thickness in patients with ALS and PD with the aim of better understanding their roles as biomarkers of disease progression. METHODS: This study recruited 21 ALS patients, 19 age-matched PD patients, and 21 agematched healthy controls...
April 2, 2024: Journal of Clinical Neurology
#18
EDITORIAL
Timothy B Meier
No abstract text is available yet for this article.
April 13, 2024: Journal of the Neurological Sciences
#19
JOURNAL ARTICLE
Leslie Grasset, Vincent Bouteloup, Federica Cacciamani, Isabelle Pellegrin, Vincent Planche, Geneviève Chêne, Carole Dufouil
BACKGROUND AND OBJECTIVES: Elevated levels of Alzheimer disease (AD) blood-based biomarkers are associated with accelerated cognitive decline. However, their distinct relationships with specific cognitive and functional domains require further investigation. We aimed at estimating the associations between AD blood-based biomarkers and the trajectories of distinct cognitive and functional domains over a 5-year follow-up period. METHODS: We conducted a clinic-based prospective study using data from the MEMENTO study, a nationwide French cohort...
May 2024: Neurology
#20
JOURNAL ARTICLE
Yutang Li, Dezhi Cao, Junda Qu, Wei Wang, Xinhui Xu, Lingyu Kong, Jianxiang Liao, Wenhan Hu, Kai Zhang, Jihan Wang, Chunlin Li, Xiaofeng Yang, Xu Zhang
OBJECTIVE: Scalp high-frequency oscillations (sHFOs) are a promising non-invasive biomarker of epilepsy. However, the visual marking of sHFOs is a time-consuming and subjective process, existing automatic detectors based on single-dimensional analysis have difficulty with accurately eliminating artifacts and thus do not provide sufficient reliability to meet clinical needs. Therefore, we propose a high-performance sHFOs detector based on a deep learning algorithm. METHODS: An initial detection module was designed to extract candidate high-frequency oscillations...
April 16, 2024: IEEE Transactions on Neural Systems and Rehabilitation Engineering
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
